SARS‑CoV‑2 continues to mutate, with some newer strains becoming less responsive to current antiviral treatments like Paxlovid. Now, researchers have identified several promising molecules that could lead to new medications capable of combating these resistant variants.
Included as a benefit
Members of Applied Microbiology International have unlimited access to The Microbiologist as a benefit of membership. Just sign in with your usual membership credentials.
Find out more about how to join.
FREE
Want to read more before deciding on a subscription? It only takes a minute to sign up for a free account and you’ll get to enjoy more free content each month.
3.75 per month / £35 annually
Get unlimited access to The Microbiologist.